• Multimedia content

  • Images (1)
    • AstraZeneca and partners act for equitable cancer care across Africa
  • All (1)
Source: AstraZeneca |

AstraZeneca and partners act for equitable cancer care across Africa

‘Accelerating Change Together for Cancer Care in Africa’ aims to tackle the growing burden of cancer across continent and improve patient outcomes

While cancer treatment developments are moving quickly, equitable access to these innovations is not there for all

SHARM EL-SHEIKH, Egypt, November 10, 2022/APO Group/ --

AstraZeneca ( and health partners today launched an initiative to transform outcomes for cancer patients across Africa.

Announced on the margins of the UN Climate Change Conference 2022, COP27, under the patronage of the Egyptian Ministry of Health, the Accelerating Change Together; Cancer Care in Africa (ACT;CCA) programme provides a platform for partners to co-create cancer care solutions that close the gaps in existing patient care pathway, from diagnosis through to treatment and beyond.

At the inaugural event, government representatives, leading clinical and health experts, patient advocates, and private sector representatives signed the ACT;CCA Coalition Declaration to reaffirm their joint commitment to advancing equitable cancer outcomes for all Africans.

“While cancer treatment developments are moving quickly, equitable access to these innovations is not there for all. Our ambition is to nurture the cancer care ecosystem in Africa, bringing together local stakeholders to co-create solutions and encourage long-term investment that leads to equitable cancer outcomes. We need joint action to reverse the alarming increase in Africa’s cancer burden, by addressing the unique barriers to cancer diagnosis and treatment, as well as building capacity that helps to make innovative care accessible to patients,” said Pelin Incesu, Area Vice President for the Middle East and Africa, AstraZeneca.

Over 700,000 deaths occurred due to cancer across the region in 2020; across Sub-Saharan Africa the current mortality rates are reaching 70 per cent in diagnosed cases. An estimated 2.1 million new cancer cases and 1.4 million deaths are expected annually by 2040 across the continent.[1] Cancers of the breast and prostate are the among the top three most prevalent.[2]

ACT;CCA focuses on driving impact in lung, breast and prostate cancer through capacity building, early screening and diagnosis and patient empowerment. It is the regional chapter of the global Accelerating Change Together (ACT) for Cancer Care (, an AstraZeneca-led effort to revolutionize the way cancer is diagnosed and treated to drive improvements in patient outcomes.

Over the next three years, ACT;CCA aims to drive screening and diagnostics covering one million people across cancer types, and to provide training for more than 10,000 healthcare professionals across 100 oncology centres.

The programme is led by a steering committee of doctors, oncology institutions and advocacy groups to guide policy intervention, share learnings across borders, and put cancer patients at the centre. Members will meet on a regular basis to drive progress on cancer initiatives.

Dr Mohsen Mokhtar, Professor of Clinical Oncology and Managing Director of Cairo University Cancer Center, President of Can-Survive-Egypt, said collaboration was key to improving cancer outcomes. “Each country joining the coalition invests heavily in cancer care programmes. We understand that by working together to develop a network that stretches beyond borders, we can close the gaps across the patient care pathway and provide solutions that improve outcomes and transform the patient journey not only for our own citizens, but across the continent.”

Dr Mary Nyangasi, Head of National Cancer Control Programme in Kenya, highlighted the disparity in care. “In some areas, the lack of disease awareness, limited diagnostic capabilities, and an absence of structured programmes for early detection and access to treatment mean that equitable cancer care is not there for all. ACT;CCA is about levelling the playing field and collaborating to transform patient outcomes.”

Launch events are planned over the coming months in Algeria, Morocco and Kenya focused on local initiatives under the ACT;CCA umbrella.

[1] Frontiers in Public Health. Mapping Cancer in Africa: A Comprehensive and Comparable Characterization of 34 Cancer Types Using Estimates From GLOBOCAN 2020. Available at Last accessed October 2022.

Distributed by APO Group on behalf of AstraZeneca.

AstraZeneca’s commitment to cancer
AstraZeneca is striving to redefine cancer care, with the ambition to advance equitable improvements in cancer outcomes for all. Achieving this goal requires partnership with the cancer community, systems and governments on a shared agenda to relieve the burden of cancer on patients, systems and society.

About Accelerating Change Together (ACT) for Cancer Care:
ACT for Cancer Care is a global, AstraZeneca-led effort to revolutionise the way cancer is diagnosed and treated to drive equitable improvement in patient outcomes and greater resilience in healthcare systems. ACT was launched at EXPO2020 in Dubai alongside key collaborators in the global oncology community. The initiative will support new and existing coalitions around a shared vision for the future of cancer care, focusing on accelerating national and regional-level public policy transformation.

About ACT for Cancer Care in Africa:
ACT for Cancer Care in Africa (ACT;CCA) represents AstraZeneca’s commitment to strengthening healthcare systems across Africa in partnership with local cancer care experts as part of the ACT network. The ambition of ACT for CCA is to guide policy improvement, drive tangible action, share learnings across domestic borders and to embed cancer patients at the centre of the healthcare system.

Partners include: The Lalla Salma Foundation, the Ministry of Health of Morocco, the Ministry of Health of Algeria, Safro, the Ministry of Health of Egypt, Mersal, the Faculty of Medical Ain Shams Research Institute, AMREF Health Africa, the Ministry of Health of Kenya, AMREF Health Africa, the National Cancer Institute of Kenya, Axios, and the Kenya Society of Haematology and Oncology.

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @AstraZeneca.